The DESTINY Lung03 trial is an open label, multicenter, phase Ib, multipart study evaluating the safety and efficacy of T DXd combined with an ICI and chemotherapy in the first line treatment of non-squamous NSCLC with HER2 overexpression. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.